The U.K.'s National Institute for Health and Care Excellence, or NICE, recommended Celgene Corp.'s pancreatic cancer drug Abraxane for routine use in the National Health Service.

Celgene agreed to a confidential price discount to make the drug more cost-effective.

Abraxane can extend the life of pancreatic cancer patients by an average of 2.4 months when added to standard chemotherapy.

The life expectancy of pancreatic cancer patients is up to six months. There are almost 10,000 new cases of pancreatic cancer each year in the U.K.